These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 33076736)

  • 1. Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients.
    Rohn B; Jansing W; Seibert FS; Pfab T; Cinkilic O; Paßfall J; Schmidt S; Babel N; Bauer F; Westhoff TH
    Ren Fail; 2020 Nov; 42(1):1067-1075. PubMed ID: 33076736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Becker MA; Schumacher HR; Espinoza LR; Wells AF; MacDonald P; Lloyd E; Lademacher C
    Arthritis Res Ther; 2010; 12(2):R63. PubMed ID: 20370912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of xanthine oxidase inhibitors on all-cause mortality in adults: a systematic review and meta-analysis.
    Nowak MM; Niemczyk M; Gołębiewski S; Pączek L
    Cardiol J; 2024; 31(3):479-487. PubMed ID: 38771265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
    Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN
    Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
    Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
    Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　- Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
    Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
    Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study.
    Steelandt A; Hittinger A; Kanagaratnam L; Kazes I; Clavel P; Bolko L; Rieu P; Salmon JH
    BMC Nephrol; 2024 Aug; 25(1):266. PubMed ID: 39164615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.